Medtronic received information via literature regarding 13-year clinical results of the medtronic mosaic porcine bioprosthesis.All data were collected from a single center between february 1994 and october 1999.The study population included 255 patients (predominantly male, mean age 67 years) who underwent aortic valve replacement and 47 patients (predominantly female, mean age 67 years) who underwent mitral valve replacement with a medtronic mosaic bioprosthetic valve (no serial numbers provided).Among aortic valve replacement patients two notable early deaths occurred within 30 days of surgery or before discharge.The first death was on postoperative day 3 due to hypertrophic obstructive cardiomyopathy with left ventricular outlet obstruction.The second death was on postoperative day 13 due to acute pericardial tamponade after aortic dissection and perforation.Based on the available information medtronic product may have been associated with these two early deaths.Among aortic valve replacement patients, adverse events included: structural valve dysfunction, pannus, thromboembolism (permanent neurological event, transient neurological attack, peripheral embolic event), acute myocardial infarction, valvular thrombosis, endocarditis, major bleeding, valve-related reoperation.Based on the available information medtronic product was associated with the adverse event(s).Among mitral valve replacement patients, adverse events included: structural valve dysfunction, thromboembolism (permanent neurological event, peripheral embolic event), endocarditis, major bleeding, and valve-related reoperation.Based on the available information medtronic product was associated with the adverse event(s).No additional adverse patient effects or product performance issues were reported.
|